Human Papillomavirus Infections and Increased Risk of Incident Osteoporosis: A Nationwide Population-Based Cohort Study

Chin, Ning-Chien; Tu, Ting-Yu; Wu, Yao‐Cheng; Yip, Hei-Tung; Wei, James Cheng‐Chung; Chang, Renin

doi:10.3390/v15041021

Cited by 2 publications

(1 citation statement)

References 64 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified individuals diagnosed with HPV infection (ICD‐9 codes 079.4, 078.1, 078.10–78.12, 078.19, 795.05, 795.09, 795.15, 795.19, 796.75, and 796.79) 17‐20 between January 1, 2008 and December 31, 2015. Figure 1 displays the flowchart for newborns with and without maternal HPV infection.…”

Section: Methodsmentioning

confidence: 99%

Maternal human papillomavirus infection and the risk of congenital malformations: A nationwide population‐based cohort study

Hsieh,

Chen,

Liao

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Previous research has explored theories regarding the vertical transmission of human papillomavirus (HPV) infection and its association with adverse pregnancy and perinatal outcomes. However, the impact of maternal HPV infection on congenital anomalies (CAs) in offspring remains relatively understudied. We conducted a population‐based cohort study linking the Taiwan Birth Registry, Taiwan Death Registry, and National Health Insurance Research Database, in which newborns born in Taiwan between 2009 and 2015 were included. We established a maternal HPV infection cohort comprising 37 807 newborns and matched them with a comparison group of 151 228 newborns at a 1:4 ratio based on index year, age, and sex. The study examined a composite outcome and subgroups of different types of congenital malformations. Differences in cumulative incidence of CAs were assessed using Kaplan–Meier curves and log‐rank tests. Adjusted hazard ratios (aHRs) were estimated using Cox proportional hazard regressions. No significant association was found between HPV infection and the broad spectrum of CAs (aHR: 1.04, 95% confidence interval [CI]: 0.98–1.10; log‐rank test p = 0.14). However, we observed a 19% increased risk of musculoskeletal CAs in the maternal HPV infection group (aHR: 1.19; 95% CI: 1.05–1.34) compared to those without maternal HPV exposure. Other factors, including the type of HPV (aHR: 0.65; 95% CI: 0.16–2.63), the timing of exposure (during or before pregnancy), and maternal age (aHR for <30 years: 1.02, 95% CI: 0.94–1.1; aHR for 30–39 years: 1.05, 95% CI: 0.99–1.11; aHR for ≥40 years: 0.88, 95% CI: 0.67–1.17), did not significantly affect the risk for any CA. In conclusion, gestation detection of HPV infection was associated with musculoskeletal CAs but not other major CAs. Prospective studies are warranted to elucidate the necessity of prenatal screening in populations at risk.

show abstract

Section: Methodsmentioning

confidence: 99%

Maternal human papillomavirus infection and the risk of congenital malformations: A nationwide population‐based cohort study

Hsieh,

Chen,

Liao

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population‐based retrospective study of 6408 patients

Dong,

Chen,

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimPatients with rheumatoid arthritis (RA) are at a higher risk of osteoporotic fractures. Studies have shown that patients with Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) experienced an increase in bone mineral density (BMD) after receiving hydroxychloroquine (HCQ) treatment, indicating a potential protective effect against osteoporosis. Therefore, this study is to examine the relationship between HCQ usage and the risk of osteoporosis in patients diagnosed with RA.MethodsThe retrospective cohort study used data from Taiwan's National Health Insurance Research Database (NHIRD) covering the period from January 2010 to December 2018, which included 14 050 newly diagnosed RA patients, subsequently divided into two groups: HCQ users and non‐users. Propensity score matching (PSM) based on sex, age, urbanization, insured unit type, insured area, and comorbidities was conducted to match the groups. The primary outcome assessed was the evaluation of the risk of osteoporosis by employing a multivariable Cox proportional hazard regression model to calculate the adjusted hazard ratio (aHR).ResultsAfter PSM, a total of 6408 RA patients were included in the analysis (3204 HCQ users and 3204 non‐users). There was no significantly higher risk of osteoporosis in HCQ users compared with non‐users, aHR = 0.99 (95% CI: 0.82–1.196). Additionally, different durations of HCQ usage demonstrated a neutral effect on the risk of osteoporosis [HCQ <90 days, aHR = 0.88 (95% CI: 0.585–1.324); HCQ 90–180 days, aHR = 0.941 (95% CI: 0.625–1.418); HCQ >180 days, aHR = 1.019 (95% CI: 0.832–1.249)].ConclusionsThe study indicates that there is no significant association between the use of HCQ and the risk of osteoporosis in patients with RA.

show abstract

Human Papillomavirus Infections and Increased Risk of Incident Osteoporosis: A Nationwide Population-Based Cohort Study

Cited by 2 publications

References 64 publications

Maternal human papillomavirus infection and the risk of congenital malformations: A nationwide population‐based cohort study

Maternal human papillomavirus infection and the risk of congenital malformations: A nationwide population‐based cohort study

Hydroxychloroquine and risk of osteoporosis in patients with rheumatoid arthritis: A population‐based retrospective study of 6408 patients

Contact Info

Product

Resources

About